126 related articles for article (PubMed ID: 28918915)
41. Acute autoimmune myocarditis and hepatitis due to ipilimumab monotherapy for malignant melanoma.
Samara Y; Yu CL; Dasanu CA
J Oncol Pharm Pract; 2019 Jun; 25(4):966-968. PubMed ID: 29444608
[TBL] [Abstract][Full Text] [Related]
42. Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis.
Franklin C; Rooms I; Fiedler M; Reis H; Milsch L; Herz S; Livingstone E; Zimmer L; Schmid KW; Dittmer U; Schadendorf D; Schilling B
Eur J Cancer; 2017 Nov; 86():248-256. PubMed ID: 29055840
[TBL] [Abstract][Full Text] [Related]
43. Endocrinopathies Related to Immune Checkpoint Inhibitors.
Khalid M; Aziz SW
Am J Ther; 2019; 26(5):e608-e609. PubMed ID: 29965803
[No Abstract] [Full Text] [Related]
44. Ipilimumab-induced colitis: a rare but serious side effect.
Hinds AM; Ahmad DS; Muenster JE; Berg ZM; Lopez KT; Holly JS; Matteson-Kome ML; Bechtold ML
Endoscopy; 2014; 46 Suppl 1 UCTN():E308-9. PubMed ID: 25058826
[No Abstract] [Full Text] [Related]
45. Refractory Neutropenia Secondary to Dual Immune Checkpoint Inhibitors That Required Second-Line Immunosuppression.
Meti N; Petrogiannis-Haliotis T; Esfahani K
J Oncol Pract; 2018 Aug; 14(8):514-516. PubMed ID: 30004823
[No Abstract] [Full Text] [Related]
46. Late-occurring toxicity induced by an immune checkpoint blockade in adjuvant treatment of a stage III melanoma patient.
Mandalà M; Merelli B; Indriolo A; Tondini C
Eur J Cancer; 2018 May; 95():130-132. PubMed ID: 29559189
[No Abstract] [Full Text] [Related]
47. Nivolumab-Induced Colitis Treated by Infliximab.
Yanai S; Nakamura S; Matsumoto T
Clin Gastroenterol Hepatol; 2017 Apr; 15(4):e80-e81. PubMed ID: 27664866
[No Abstract] [Full Text] [Related]
48. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
Petrella TM; Robert C; Richtig E; Miller WH; Masucci GV; Walpole E; Lebbe C; Steven N; Middleton MR; Hille D; Zhou W; Ibrahim N; Cebon J
Eur J Cancer; 2017 Nov; 86():115-124. PubMed ID: 28987768
[TBL] [Abstract][Full Text] [Related]
49. Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort.
Jung M; Lee J; Kim TM; Lee DH; Kang JH; Oh SY; Lee SJ; Shin SJ
Cancer Res Treat; 2017 Jan; 49(1):44-53. PubMed ID: 27121719
[TBL] [Abstract][Full Text] [Related]
50. Case Report of Ipilimumab-Induced Diffuse, Nonnecrotizing Granulomatous Lymphadenitis and Granulomatous Vasculitis.
Arellano K; Mosley JC; Moore DC
J Pharm Pract; 2018 Apr; 31(2):227-229. PubMed ID: 29279030
[TBL] [Abstract][Full Text] [Related]
51. Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins.
Spänkuch I; Gassenmaier M; Tampouri I; Noor S; Forschner A; Garbe C; Amaral T
Eur J Cancer; 2017 Aug; 81():203-205. PubMed ID: 28641200
[No Abstract] [Full Text] [Related]
52. [Alopecia areata under ipilimumab].
Amini-Adle M; Dalle S
Ann Dermatol Venereol; 2018; 145(6-7):465-466. PubMed ID: 29653853
[No Abstract] [Full Text] [Related]
53. Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome.
Mirza S; Hill E; Ludlow SP; Nanjappa S
Melanoma Res; 2017 Jun; 27(3):271-273. PubMed ID: 28146044
[TBL] [Abstract][Full Text] [Related]
54. Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response.
Gonzalez-Cao M; Boada A; Teixidó C; Fernandez-Figueras MT; Mayo C; Tresserra F; Bustamante J; Viteri S; Puertas E; Santarpia M; Riso A; Barron F; Karachaliou N; Rosell R
Oncotarget; 2016 Aug; 7(35):56619-56627. PubMed ID: 27447748
[TBL] [Abstract][Full Text] [Related]
55. Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy.
Bamias G; Delladetsima I; Perdiki M; Siakavellas SI; Goukos D; Papatheodoridis GV; Daikos GL; Gogas H
Cancer Invest; 2017 Aug; 35(7):443-455. PubMed ID: 28548891
[TBL] [Abstract][Full Text] [Related]
56. Ipilimumab-induced toxicities and the gastroenterologist.
Cheng R; Cooper A; Kench J; Watson G; Bye W; McNeil C; Shackel N
J Gastroenterol Hepatol; 2015 Apr; 30(4):657-66. PubMed ID: 25641691
[TBL] [Abstract][Full Text] [Related]
57. Ipilimumab Induced Hypophysitis: MRI Findings in a Series of 3 Cases.
Wadhwa V
J Ark Med Soc; 2017 May; 113(11):270-272. PubMed ID: 30351740
[TBL] [Abstract][Full Text] [Related]
58. Ipilimumab-related hypophysitis may precede severe CNS immune attack.
Köessler T; Olivier T; Fertani S; Marinari E; Dutoit V; Dietrich PY
Ann Oncol; 2016 Oct; 27(10):1975-6. PubMed ID: 27358386
[No Abstract] [Full Text] [Related]
59. Lymphocytic colitis-like pattern of mucosal injury and the challenges in diagnosing cancer immunotherapy-related toxicity.
Grover S; Srivastava A
Cancer; 2019 Jun; 125(11):1768-1770. PubMed ID: 30892689
[No Abstract] [Full Text] [Related]
60. A 60-Year-Old Man With Progressive Anemia While Receiving Checkpoint Blockade Therapy for Relapsed Myelofibrosis.
Goodman AM; Rust M; Costello C; Ball ED
Oncology (Williston Park); 2017 Feb; 31(2):122-4, 126-8. PubMed ID: 28205192
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
